Serotonergic Antidepressant Use and Risk of Clinically Significant Bleeding in Thrombocytopenic Hematologic Malignancy Patients
In patients with HM and thrombocytopenia, SRI exposure was not associated with an increased risk of CSB. Given the small study size, assessment of patient-specific risks versus benefits should still be considered when prescribing SRI therapy in this patient population.
Authors
- Marissa Olson (ORCID: https://orcid.org/0000-0003-1537-7145)
- Emily Owen (ORCID: https://orcid.org/0000-0002-6095-4805)
- Colleen McEvoy (ORCID: https://orcid.org/0009-0008-2566-191X)
- Eunsun Gill (ORCID: https://orcid.org/0000-0002-3504-2070)
- Hannah Delp
Institutions
- Barnes-Jewish Hospital (US)
- Washington University in St. Louis (US)
Publication Details
- Journal
- Annals of Pharmacotherapy
- Published
- 2025-03-15
- DOI
- https://doi.org/10.1177/10600280251319757
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 0.00